Geller DS, Gorlick R. Osteosarcoma: a review of diagnosis, management, and treatment strategies. Clin Adv Hematol Oncol. 2010;8(10):705–18.
Siegel RL, Miller KD, Jemal A. Cancer statistics, 2018. CA Cancer J Clin. 2018;68(1):7–30.
Link MP, Goorin AM, Miser AW, et al. The effect of adjuvant chemotherapy on relapse-free survival in patients with osteosarcoma of the extremity. N Engl J Med. 1986;314(25):1600–6.
Luetke A, Meyers PA, Lewis I, Juergens H. Osteosarcoma treatment—where do we stand? A state of the art review. Cancer Treat Rev. 2014;40(4):523–32.
Shimose S, Kubo T, Fujimori J, Furuta T, Ochi M. A novel assessment method of serum alkaline phosphatase for the diagnosis of osteosarcoma in children and adolescents. J Orthop Sci. 2014;19(6):997–1003.
Marais LC, Bertie J, Rodseth R, Sartorius B, Ferreira N. Pre-treatment serum lactate dehydrogenase and alkaline phosphatase as predictors of metastases in extremity osteosarcoma. J Bone Oncol. 2015;4(3):80–4.
Fu Y, Lan T, Cai H, Lu A, Yu W. Meta-analysis of serum lactate dehydrogenase and prognosis for osteosarcoma. Medicine. 2018;97(19):e0741.
Memczak S, Jens M, Elefsinioti A, et al. Circular RNAs are a large class of animal RNAs with regulatory potency. Nature. 2013;495(7441):333–8.
Hansen TB, Jensen TI, Clausen BH, et al. Natural RNA circles function as efficient microRNA sponges. Nature. 2013;495(7441):384–8.
Tay Y, Rinn J, Pandolfi pp. The multilayered complexity of ceRNA crosstalk and competition. Nature. 2014;505(7483):344–52.
Pan F, Zhang J, Tang B, Jing L, Qiu B, Zha Z. The novel circ_0028171/miR-218-5p/IKBKB axis promotes osteosarcoma cancer progression. Cancer Cell Int. 2020;20:484.
Li X, Liu Y, Zhang X, et al. Circular RNA hsa_circ_0000073 contributes to osteosarcoma cell proliferation, migration, invasion and methotrexate resistance by sponging miR-145-5p and miR-151-3p and upregulating NRAS. Aging. 2020;12(14):14157–73.
Zhang C, Zhou H, Yuan K, Xie R, Chen C. Overexpression of hsa_circ_0136666 predicts poor prognosis and initiates osteosarcoma tumorigenesis through miR-593-3p/ZEB2 pathway. Aging. 2020;12(11):10488–96.
Yang C, Tian Y, Zhao F, et al. Bone microenvironment and osteosarcoma metastasis. Int J Mol Sci. 2020. https://doi.org/10.3390/ijms21196985.
Cersosimo F, Lonardi S, Bernardini G, et al. Tumor-associated macrophages in osteosarcoma: from mechanisms to therapy. Int J Mol Sci. 2020. https://doi.org/10.3390/ijms21155207.
Bindea G, Mlecnik B, Tosolini M, et al. Spatiotemporal dynamics of intratumoral immune cells reveal the immune landscape in human cancer. Immunity. 2013;39(4):782–95.
Charoentong P, Finotello F, Angelova M, et al. Pan-cancer immunogenomic analyses reveal genotype-immunophenotype relationships and predictors of response to checkpoint blockade. Cell Rep. 2017;18(1):248–62.
Gentles AJ, Newman AM, Liu CL, et al. The prognostic landscape of genes and infiltrating immune cells across human cancers. Nat Med. 2015;21(8):938–45.
Newman AM, Liu CL, Green MR, et al. Robust enumeration of cell subsets from tissue expression profiles. Nat Methods. 2015;12(5):453–7.
Ali HR, Chlon L, Pharoah PD, Markowetz F, Caldas C. Patterns of immune infiltration in breast cancer and their clinical implications: a gene-expression-based retrospective study. PLoS Med. 2016;13(12):e1002194.
Nabergoj S, Mlinarič-Raščan I, Jakopin Ž. Harnessing the untapped potential of nucleotide-binding oligomerization domain ligands for cancer immunotherapy. Med Res Rev. 2019;39(5):1447–84.
Chen C, Xie L, Ren T, Huang Y, Xu J, Guo W. Immunotherapy for osteosarcoma: fundamental mechanism, rationale, and recent breakthroughs. Cancer Lett. 2021;500:1–10.
Miwa S, Shirai T, Yamamoto N, et al. Current and emerging targets in immunotherapy for osteosarcoma. J Oncol. 2019;2019:7035045.
Li B, Zhu L, Lu C, et al. circNDUFB2 inhibits non-small cell lung cancer progression via destabilizing IGF2BPs and activating anti-tumor immunity. Nat Commun. 2021;12(1):295.
Huang XY, Zhang PF, Wei CY, et al. Circular RNA circMET drives immunosuppression and anti-PD1 therapy resistance in hepatocellular carcinoma via the miR-30-5p/snail/DPP4 axis. Mol Cancer. 2020;19(1):92.
Hsu MT, Coca-Prados M. Electron microscopic evidence for the circular form of RNA in the cytoplasm of eukaryotic cells. Nature. 1979;280(5720):339–40.
Kristensen LS, Ebbesen KK, Sokol M, et al. Spatial expression analyses of the putative oncogene ciRS-7 in cancer reshape the microRNA sponge theory. Nat Commun. 2020;11(1):4551.
Li J, Ma M, Yang X, et al. Circular HER2 RNA positive triple negative breast cancer is sensitive to Pertuzumab. Mol Cancer. 2020;19(1):142.
Wang H, Wei M, Kang Y, Xing J, Zhao Y. Circular RNA circ_PVT1 induces epithelial-mesenchymal transition to promote metastasis of cervical cancer. Aging. 2020. https://doi.org/10.18632/aging.103679.
Chen J, Liu G, Wu Y, et al. CircMYO10 promotes osteosarcoma progression by regulating miR-370-3p/RUVBL1 axis to enhance the transcriptional activity of β-catenin/LEF1 complex via effects on chromatin remodeling. Mol Cancer. 2019;18(1):150.
Shen S, Yao T, Xu Y, Zhang D, Fan S, Ma J. CircECE1 activates energy metabolism in osteosarcoma by stabilizing c-Myc. Mol Cancer. 2020;19(1):151.
Zhang C, Zheng JH, Lin ZH, et al. Profiles of immune cell infiltration and immune-related genes in the tumor microenvironment of osteosarcoma. Aging. 2020;12(4):3486–501.
Tu J, Wu F, Chen L, et al. Long non-coding RNA PCAT6 induces M2 polarization of macrophages in Cholangiocarcinoma via modulating miR-326 and RhoA-ROCK signaling pathway. Front Oncol. 2020;10:605877.
Zhang Y, Feng J, Fu H, et al. Coagulation factor X regulated by CASC2c recruited macrophages and induced M2 polarization in glioblastoma multiforme. Front Immunol. 2018;9:1557.
Shao L, He Q, Wang J, et al. MicroRNA-326 attenuates immune escape and prevents metastasis in lung adenocarcinoma by targeting PD-L1 and B7–H3. Cell Death Discov. 2021;7(1):145.
Lu D, Liu L, Sun Y, et al. The phosphatase PAC1 acts as a T cell suppressor and attenuates host antitumor immunity. Nat Immunol. 2020;21(3):287–97.
Dai Z, Liu P. High copy number variations, particular transcription factors, and low immunity contribute to the stemness of prostate cancer cells. J Transl Med. 2021;19(1):206.
Cai H, Miao M, Wang Z. miR-214-3p promotes the proliferation, migration and invasion of osteosarcoma cells by targeting CADM1. Oncol Lett. 2018;16(2):2620–8.
Fujimoto H, Saito Y, Ohuchida K, et al. Deregulated mucosal immune surveillance through gut-associated regulatory T cells and PD-1(+) T cells in human colorectal cancer. J Immunol. 2018;200(9):3291–303.
Zhang J, Zhang Y, Lv H, et al. Human stem cells from the apical papilla response to bacterial lipopolysaccharide exposure and anti-inflammatory effects of nuclear factor I C. J Endod. 2013;39(11):1416–22.
Li L, Ameri AH, Wang S, et al. EGR1 regulates angiogenic and osteoclastogenic factors in prostate cancer and promotes metastasis. Oncogene. 2019;38(35):6241–55.
Liu N, Zhang J, Yin M, et al. Inhibition of xCT suppresses the efficacy of anti-PD-1/L1 melanoma treatment through exosomal PD-L1-induced macrophage M2 polarization. Mol Ther. 2021;29(7):2321–34.
Li F, Wang T, Huang Y. POU2F1 induces the immune escape in lung cancer by up-regulating PD-L1. Am J Transl Res. 2021;13(2):672–83.
Allen TA, Cullen MM, Hawkey N, et al. A zebrafish model of metastatic colonization pinpoints cellular mechanisms of circulating tumor cell extravasation. Front Oncol. 2021;11:641187.
Nie Z, Gao W, Zhang Y, et al. STAG2 loss-of-function mutation induces PD-L1 expression in U2OS cells. Ann Transl Med. 2019;7(7):127.
Mieszkowska A, Beaumont H, Martocq L, et al. Phenolic-enriched collagen fibrillar coatings on titanium alloy to promote osteogenic differentiation and reduce inflammation. Int J Mol Sci. 2020. https://doi.org/10.3390/ijms21176406.
Janus P, Pakuła-Cis M, Kalinowska-Herok M, et al. NF-κB signaling pathway is inhibited by heat shock independently of active transcription factor HSF1 and increased levels of inducible heat shock proteins. Genes Cells. 2011;16(12):1168–75.
Ji X, Shan L, Shen P, He M. Circular RNA circ_001621 promotes osteosarcoma cells proliferation and migration by sponging miR-578 and regulating VEGF expression. Cell Death Dis. 2020;11(1):18.
Wang J, Cao L, Wu J, Wang Q. Long non-coding RNA SNHG1 regulates NOB1 expression by sponging miR-326 and promotes tumorigenesis in osteosarcoma. Int J Oncol. 2018;52(1):77–88.
Cao L, Wang J, Wang PQ. MiR-326 is a diagnostic biomarker and regulates cell survival and apoptosis by targeting Bcl-2 in osteosarcoma. Biomed Pharmacother. 2016;84:828–35.
Trieb K, Sulzbacher I, Kubista B. Bcl-2 correlates with localization but not outcome in human osteosarcoma. Oncol Lett. 2013;6(2):559–61.
Fu T, Xia C, Li Z, Wu H. Lack of association between bcl-2 expression and prognosis of osteosarcoma: a meta-analysis. Int J Clin Exp Med. 2015;8(6):9093–9.
Ferrari S, Bertoni F, Zanella L, et al. Evaluation of P-glycoprotein, HER-2/ErbB-2, p53, and Bcl-2 in primary tumor and metachronous lung metastases in patients with high-grade osteosarcoma. Cancer. 2004;100(9):1936–42.
McEachron TA, Triche TJ, Sorenson L, Parham DM, Carpten JD. Profiling targetable immune checkpoints in osteosarcoma. Oncoimmunology. 2018;7(12):e1475873.
Liu JL, Li J, Xu JJ, et al. MiR-144 Inhibits tumor growth and metastasis in osteosarcoma via dual-suppressing RhoA/ROCK1 signaling pathway. Mol Pharmacol. 2019;95(4):451–61.
Zheng B, Zhou C, Qu G, et al. VEGFR2 promotes metastasis and PD-L2 expression of human osteosarcoma cells by activating the STAT3 and RhoA-ROCK-LIMK2 pathways. Front Oncol. 2020;10:543562.
Zhang A, Yan T, Wang K, Huang Z, Liu J. PI3Kα isoform-dependent activation of RhoA regulates Wnt5a-induced osteosarcoma cell migration. Cancer Cell Int. 2017;17:27.
Jia F, Zhang Z, Zhang X. MicroRNA-338-3p inhibits tumor growth and metastasis in osteosarcoma cells by targeting RUNX2/CDK4 and inhibition of MAPK pathway. J Cell Biochem. 2019;120(4):6420–30.
Cao R, Shao J, Hu Y, et al. microRNA-338-3p inhibits proliferation, migration, invasion, and EMT in osteosarcoma cells by targeting activator of 90 kDa heat shock protein ATPase homolog 1. Cancer Cell Int. 2018;18:49.
Xiang D, Li Y, Lin Y. Circular RNA circCCDC66 contributes to malignant phenotype of osteosarcoma by sponging miR-338-3p to upregulate the expression of PTP1B. Biomed Res Int. 2020;2020:4637109.
Zhang H, Wang J, Ren T, et al. LncRNA CASC15 is upregulated in osteosarcoma plasma exosomes and CASC15 knockdown inhibits osteosarcoma progression by regulating miR-338-3p/RAB14 Axis. Onco Targets Ther. 2020;13:12055–66.
Dai N, Zhong ZY, Cun YP, et al. Alteration of the microRNA expression profile in human osteosarcoma cells transfected with APE1 siRNA. Neoplasma. 2013;60(4):384–94.
Molist C, Navarro N, Giralt I, et al. miRNA-7 and miRNA-324-5p regulate alpha9-Integrin expression and exert anti-oncogenic effects in rhabdomyosarcoma. Cancer Lett. 2020;477:49–59.
Li Z, Li N, Sun X, Wang J. FAM98A promotes cancer progression in endometrial carcinoma. Mol Cell Biochem. 2019;459(1–2):131–9.
Zheng R, Liu Q, Wang T, Wang L, Zhang Y. FAM98A promotes proliferation of non-small cell lung cancer cells via the P38-ATF2 signaling pathway. Cancer Manag Res. 2018;10:2269–78.
Liu T, Wang Z, Dong M, Wei J, Pan Y. MicroRNA-26a inhibits cell proliferation and invasion by targeting FAM98A in breast cancer. Oncol Lett. 2021;21(5):367.
Fujiwara T, Ye S, Castro-Gomes T, et al. PLEKHM1/DEF8/RAB7 complex regulates lysosome positioning and bone homeostasis. JCI Insight. 2016;1(17):e86330.
Wang Y, Ye W, Liu Y, Mei B, Liu X, Huang Q. Osteoporosis genome-wide association study variant c.3781 C>A is regulated by a novel anti-osteogenic factor miR-345-5p. Hum Mutat. 2020;41(3):709–18.
Hawkins AG, Basrur V, da Veiga LF, et al. The Ewing sarcoma secretome and its response to activation of Wnt/beta-catenin signaling. Mol Cell Proteomics. 2018;17(5):901–12.
He M, Wang Z, Zhao J, Chen Y, Wu Y. COL1A1 polymorphism is associated with risks of osteosarcoma susceptibility and death. Tumour Biol. 2014;35(2):1297–305.
Yao L, Zhou Y, Sui Z, et al. HBV-encoded miR-2 functions as an oncogene by downregulating TRIM35 but upregulating RAN in liver cancer cells. EBioMedicine. 2019;48:117–29.
Zaoui K, Boudhraa Z, Khalifé P, Carmona E, Provencher D, Mes-Masson AM. Ran promotes membrane targeting and stabilization of RhoA to orchestrate ovarian cancer cell invasion. Nat Commun. 2019;10(1):2666.
Dell’Anno I, Barbarino M, et al. EIF4G1 and RAN as possible drivers for malignant pleural mesothelioma. Int J Mol Sci. 2020. https://doi.org/10.3390/ijms21144856.
Jain N, Das B, Mallick B. Restoration of microRNA-197 expression suppresses oncogenicity in fibrosarcoma through negative regulation of RAN. IUBMB Life. 2020;72(5):1034–44.
Li J, Rao B, Yang J, et al. Dysregulated m6A-related regulators are associated with tumor metastasis and poor prognosis in osteosarcoma. Front Oncol. 2020;10:769.